Krystal Biotech
KRYS
98 hedge funds and large institutions have $623M invested in Krystal Biotech in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 47 increasing their positions, 30 reducing their positions, and 16 closing their positions.
57% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 30
6% more capital invested
Capital invested by funds: $589M → $623M (+$34.1M)
1.31% more ownership
Funds ownership: 72.16% → 73.47% (+1.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less funds holding
Funds holding: 110 → 98 (-12)
59% less call options, than puts
Call options by funds: $431K | Put options by funds: $1.06M
75% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$11.9M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$10.7M |
| 3 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$7.94M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.41M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$23.4M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$7.61M |
| 3 |
State Street
Boston,
Massachusetts
|
-$4.45M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$1.84M |
| 5 |
Renaissance Technologies
New York
|
-$1.82M |
KRYS Hedge Fund Activity: Q3 2020 in Review
98 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q3 2020, worth a combined $623M — up 5.8% from $589M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of KRYS and 4 opened new positions — a net loss of 12 holders — while 30 trimmed existing stakes and 47 added.
The largest buyer was Pictet Asset Management (UK), adding an estimated $11.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $23.4M.
- 98 institutional investors held Krystal Biotech (KRYS) as of Q3 2020, down from 110 in Q2 2020.
- Funds reported $623M of Krystal Biotech stock for Q3 2020, up 5.8% quarter-over-quarter.
- 4 funds opened new Krystal Biotech positions in Q3 2020 and 16 closed out, a net change of -12 holders.
- The largest Krystal Biotech buyer in Q3 2020 was Pictet Asset Management (UK), an estimated $11.9M added.
- The largest Krystal Biotech seller in Q3 2020 was T. Rowe Price Associates, an estimated $23.4M sold.
Based on aggregated 13F filings for Q3 2020.